Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform

Skipper Limited: From Order Book To Earnings

Inox India Ltd: Backbone For Industrial Gases And Clean Energy

Entero Healthcare: New Titan of Pharma Distribution

Entero Healthcare: Consolidating India’s Fragmented Healthcare Supply Chain

Polycab India: FMEG Margin Inflection Becomes the Key Re-Rating Lever

Diamond Power Infrastructure: Growing Extra High Voltage and Data Center Segment

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Entero Healthcare Solutions / Equity Bottom-Up

<ul>
<li>Management expects FY27 MedTech revenue to cross INR 1,000 crore and says Q1 performance is comfortably tracking above that threshold.</li>
<li>MedTech is largely demand generation, not only fulfilment, giving Entero a structurally better opportunity to earn higher gross and EBITDA margins.</li>
<li>Mix shift can lift group margins even if core pharma remains competitive, creating earnings growth faster than revenue and a potential re-rating catalyst.</li>
</ul>


Management expects FY27 MedTech revenue to cross INR 1,000 crore and says Q1 performance is comfortably tracking above that threshold.
MedTech is largely demand generation, not only fulfilment, giving Entero a structurally better opportunity to earn higher gross and EBITDA margins.
Mix shift can lift group margins even if core pharma remains competitive, creating earnings growth faster than revenue and a potential re-rating catalyst.


Entero Healthcare: The Hidden MedTech Opportunity